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OBJECTIVES:There is a paucity of published literature or patient-reported outcome
instruments investigating the concept of muscle weakness/wasting and its impact
on advanced pancreatic cancer patients’ lives. The objective of this study was to
explore locally advanced or metastatic pancreatic cancer patients’ experience of
muscle weakness/wasting and its impact on their lives and develop a conceptual
model to illustrate the key concepts raised and their inter-relationships.
METHODS: A cross-sectional qualitative study using non-probabilistic purposive
sampling strategy recruited patients through 3 clinical sites in the United States.
An interview discussion guide was developed using information obtained from a
review of published literature. In-depth semi-structured interviews were con-
ducted over the telephone. Data was analysed using a thematic analysis approach.
A codebook developed during qualitative analysis was used as a basis for the de-
velopment of the conceptual model. The conceptual model was reviewed by an
expert clinician.RESULTS:Twenty-three advanced pancreatic cancer patientswho
experienced muscle weakness were interviewed. The sample included a wide age
range (mean 63.3; range 38 - 87) and bothmale (78.3%) and female (21.7%) patients.
Analysis of the qualitative data found that several areas of patient’s lives were
impacted by the muscle weakness/wasting they experienced. Patients identified a
number of conceptswhich fell into the domains of physical activities of daily living,
physical performance, social functioning, leisure activities, appearance, emotional
impact and work. A conceptual model was developed to graphically illustrate the
relationship between the concepts and their moderating factors. CONCLUSIONS:
Muscle weakness and wasting have a noticeable and wide reaching negative im-
pact on the lives of patients with advanced pancreatic cancer. This research iden-
tifies concepts of concern that could be explored as potential endpoints in future
clinical trials.
PCN103
VARIATION IN HEALTH-RELATED QUALITY OF LIFE BY AGE AMONG PATIENTS
WITH CHRONIC LYMPHOCYTIC LEUKEMIA
Pashos CL1, Flowers CR2, Weiss M3, Lamanna N4, Farber C5, Kipps TJ6, Lerner S7, Kay N8,
Sharman J9, Grinblatt DL10, Flinn IW11, Kozloff MF12, Swern AS13, Khan Z13, Street TK13,
Sullivan KA13, Harding G14, Keating MJ7
1United BioSource Corporation, Lexington, MA, USA, 2Emory University, Atlanta, GA, USA,
3Thomas Jefferson University, Philadelphia, PA, USA, 4Memorial Sloan-Kettering Cancer Center,
New York, NY, USA, 5Hematology Oncology Northern New Jersey, Morristown, NJ, USA, 6Moores
Cancer Center, University of California - San Diego, La Jolla, CA, USA, 7MD Anderson Cancer
Center, Houston, TX, USA, 8Mayo Clinic - Rochester, Rochester, MN, USA, 9US Oncology,
Springfield, OR, USA, 10NorthShore University Health System, Evanston, IL, USA, 11Sarah
Cannon Research Institute, Nashville, TN, USA, 12Ingalls Cancer Research Center, Harvey, IL,
USA, 13Celgene Corporation, Summit, NJ, USA, 14United BioSource Corporation, Bethesda, MD,
USA
OBJECTIVES: Among patients with chronic lymphocytic leukemia (CLL), advanced
age is typically associated with limited functional status. We examined the rela-
tionship between age and health-related quality of life (HRQOL) for CLL patients
treated in the United States (US).METHODS: Data were collected in Connect® CLL,
a prospective US observational registry begun in 2010. Patient demographics and
clinical characteristics were provided by clinicians. Patient HRQOL was self-re-
ported in the clinic at enrollment. Patients completed the Functional Assessment
of Cancer Therapy-Leukemia (FACT-Leu), EQ-5D, and Brief Fatigue Inventory (BFI).
FACT-Leu, EQ-5D and BFI scores were analyzed by age group (65, 65-74, 74).
Statistical significance of differences was ascertained by ANOVA (SAS 9.1).
RESULTS: Baseline HRQOL data were reported by 899 patients from 161 centers.
Patients were predominantly male (63%) and white (90%) with mean age at 69
(standard deviation 11) years. FACT-Leu results suggest that overall HRQOL is bet-
ter among the 65-74 cohort than either younger or older patients (p0.0421), re-
flecting better physical (p0.0100) and CLL-specific (p0.0083) scores. FACT-G
scores are similar among the two older groups and better than the younger patients
(p0.0275), reflecting better emotional well-being (p0.0127). EQ-5D data indicate
thatmobility is most impaired in the oldest group compared to the younger groups
(p0.0001), and that usual activities (p0.0009) and pain/discomfort (p0.0001) are
worse in both younger and older cohorts compared to those 65-74. No significant
differences were observed in fatigue measured by the BFI, or in overall HRQOL
measured by the EQ-5D Visual Analogue Scale. CONCLUSIONS: Connect® CLL reg-
istry results indicate that overall HRQOL is not worse with older age, as both
younger and older age groups have worse HRQOL in certain domains. Future anal-
yses should determine how HRQOL is affected over time with treatment and
changes in disease. These results serve as a baseline reference.
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OBJECTIVES: Measurements of Eastern Cooperative Oncology Group Performance
Status (ECOG-PS) are widely used to assess disease progression, determine appro-
priate treatment and prognosis; however, ECOG-PS over time in routine clinical
practice is rarely published. This study examined ECOG-PS in patients with stage
III/IV melanoma during 1-year from diagnosis in community oncology clinics.
METHODS: Electronic medical records from 47 oncology clinics across the US were
used for this analysis. Patients who had melanoma diagnosis, stage information,
and ECOG-PS scores were included. Patient clinical, demographic, and treatment
characteristics were described. ECOG-PS at diagnosis of stage III and IV melanoma
and at every threemonthswere analyzed.Mixedmodel analysiswas undertaken to
examine changes in ECOG-PS over time. RESULTS:A total of 266 patients (102 stage
III and 164 stage IV) were included in this study. At baseline, stage IV patients had
significantly worse mean ECOG-PS scores than stage III patients (0.79 vs. 0.35,
p0.0001). In patients with both baseline and at least one post-diagnosis assess-
ment (84 and 110 patients with stage III and IV, respectively), mixed model esti-
mated mean ECOG-PS scores changed from 0.69 at baseline to 1.14 at 1-year for
stage IV patients andwere relatively stable for stage III patients (0.47 (baseline) and
0.54 (1-year). There were 25 stage III and 43 stage IV patients who received drug
treatments for melanoma. The majority of stage III patients (84%) received Inter-
feron only; while 44.2% of stage IV patients received carboplatinpaclitaxel, 32.6%
dacarbazine, and 11.6% cisplatin. Among drug treated patients with stage IV, wors-
ening ECOG-PS over time (from 0.87 at baseline to 1.14 at one year) was observed.
CONCLUSIONS: In patients with advanced melanoma treated in community on-
cology practices, worse ECOG-PS scores and faster deterioration were observed for
patients diagnosed with stage IV compared to stage III. Even in patients treated
with systemic therapies, worsening ECOG-PS was also observed over time.
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OBJECTIVES: Prolongation of survival or prevention of bone metastases are the
main objectives of phase 3 studies in MPC patients refractory to hormone therapy
or castration resistant (HRPC/CRPC). In addition to efficacy, PROs and tolerability
should be assessed to define treatment benefit, as PROs (eg. quality of life [QOL] and
pain response) measure the patient’s subjective experience and can be correlated
with hard outcomes (eg, pain intensity and survival). A systematic review evalu-
ated the number of studies reporting PROs in HRPC/CRPC; tolerability was a sec-
ondary objective.METHODS: A predefined search strategy was used (2007-2011) in
Medline, EMBASE, Cochrane Library, conference proceedings (ASCO/ESMO), AHRQ,
NICE, and NHS HEED. Controlled clinical trials, retrospective cohort studies, and
literature reviews were included. Studies in children, non-English language stud-
ies, case reports/series, and studies with preliminary/incomplete results were
excluded. RESULTS: Of 79 studies identified, only 14 (18%) evaluated PROs and
tolerability. The most common PRO was pain, measured using the Present Pain
Intensity (PPI) instrument. Abiraterone showed statistically significant improve-
ments in survival and pain response. Cabazitaxel did not show improvement in
pain response, despite survival benefit. Bone-targeted agents (zoledronic acid/de-
nosumab) prolonged the time to first on-study skeletal related event (SRE) but did
not assess PROs. Radium-223, a new bone-targeted radiopharmaceutical agent
emitting -particles, included QOL as a secondary endpoint and showed survival
benefit. Toxicities of the new therapies also require careful consideration. Fluid
retention, hypertension, and hypokalemia are characteristic toxicities with abi-
raterone (predominately Grade 1/2). Cabazitaxel has a high incidence of Grade 3/4
neutropenia (82%), febrile neutropenia (8%), and diarrhea (6%). Radium-223 is well
tolerated with a low incidence of Grade 3/4 neutropenia (2%). CONCLUSIONS: PROs
are incorporated in studies of new therapies for MPC, although mainly as second-
ary endpoints with delayed reporting of results. Therefore, safety profiles play an
important role in individualized treatment selections.
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OBJECTIVES: The FDA and EMA have published guidance documents to direct the
development and inclusion of patient-reported outcomes (PROs) for drug approval
and labeling. The Center for Medical Technology Policy’s (CMTP) objective is to
develop parallel guidance for post-regulatory decision makers for the appropriate
inclusion of patient-reported outcomemeasures in the design and implementation
of CER clinical trials.METHODS:A semi-structured questionnaire pertaining to the
use of PROs in CER was developed based on a review of scientific literature and
consultation with PRO study methodologists. In-depth interviews were conducted
with 15 individuals from the clinical research, clinical practice, regulatory, payer,
and patient communities. From these findings, an initial list of recommendations
were developed, and the Center for Medical Technology Policy (CMTP) workedwith
a multidisciplinary technical working group of leading medical researchers, ePRO
consultants, and patient advocates to establish a concrete set of recommenda-
tions. Fifteen recommendations were incorporated in the guidance document and
posted on CMTP’s website for a 2-month public comment period. Organizations
were contacted to provide feedback through an online survey that elicited both
Likert-scale questions and open comments. The guidance was then revised.
RESULTS:A list of 12 “core” symptomswas identified as key items tomeasure in all
late-phase studies for cancer trials: anorexia, anxiety, constipation, depression,
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